Toxys awarded € 50.000 by EIT Health to develop ReproTracker – an in vitro assay for reproductive toxicity

Toxys awarded € 50.000 by EIT Health to develop ReproTracker – an in vitro assay for reproductive toxicity

cs4m-tgwiaae2oo21 September 2016 – Today Toxys was awarded a €50.000 grant for a head-start project to further develop the ReproTracker. Toxys is dedicated to develop innovative in vitro toxicity assays that provide insight into the mechanisms of toxicity. Toxys’ lead product ToxTracker is a genotoxicity assay that provides mechanistic insight into genotoxicity and is available on the market. Toxys has now applied their knowledge and expertise to validate a novel assay, ReproTracker, which provides mechanistic insight into reproductive toxicity.

About ReproTracker

ReproTracker is an in vitro assay to visualise the key events during early embryonic development and thereby reliably assess the potential developmental toxicity hazards of new drugs and products. ReproTracker meets the strong demand from industry for better in vitro tests to predict human health hazards of their products during the early phases of product development. The assay is build on the technical and scientific background that has been developed by Toxys. We will combine our expertise on stem cell differentiation with the reporter technology that was applied in our ToxTracker assay and generate the ReproTracker reporter system that can identify developmental toxicity upon exposure to novel drugs, chemicals and materials.

About EIT Health

Toxys was awarded the head-start project from EIT Health, which is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the foundations of healthcare and thus promote the future conditions for healthier living and wellbeing of people across Europe. EIT Health is leveraging the expertise of more than 130 leading organisations spanning key areas of healthcare such as Pharma, MedTech, Payers, Research Institutions and Universities. Chosen by the European Institute of Innovation and Technology (EIT) to form EIT Health, the consortium offers best-in-class research capabilities, higher education and business expertise. With a budget of 2 billion EUR over the next decade, it will purposefully invest in Europe’s best entrepreneurial talents and creative minds to foster the development and commercialisation of smart product and service solutions in the health sector, addressing the challenges imposed by demographic change and ageing societies.

If you have any questions about Toxys or ReproTracker, please contact us via

No Comments

Leave a reply